Drug-drug interactions (DDIs) are often caused by the effects of membrane transporters on drug absorption and disposition in the body. Transporters, such as efflux and uptake, can have significant impacts on a drug’s safety and efficacy — either alone or in conjunction with drugmetabolizing enzymes.

Predicting and understanding DDIs through in vitro studies is vital to gaining insights into their potential causes and consequences. It is therefore necessary that drug developers partner with contract research organizations (CROs) that excel in conducting in vitro studies and generating the required data to determine whether clinical DDI studies are necessary.

DOWNLOAD WHITE PAPER

🧬 Exciting Innovations in Drug Development! 🌟

Small molecules and antibodies have long been primary channels of drug development, but there's another rising player on the scene - Oligonucleotides (OGNTs). These short DNA/RNA strands are revolutionizing personalized medicine, offering precise disease-targeting at the source.

💡 Why are OGNTs a game-changer?

1. Drugging the "undruggable": OGNTs open doors to tackle previously untreatable diseases.
2. Accelerating drug development: Speeding up the process, saving lives.
3. Driving technological advancements: Paving the way for cutting-edge therapies.

The global market is soaring, projected to hit $5.7 trillion by 2030! 📈 Be part of this healthcare revolution. Learn more in our White Paper.

DOWNLOAD WHITE PAPER

Host cell protein (HCP) profiling is a core component of large molecule biopharmaceutical protein characterization. To ensure the safety of protein drug products, these residual impurities must be measured, monitored, and controlled to set specifications during biotherapeutic manufacturing.

Greg Kilby, Vice President of Technology and Bioanalysis at Alliance Pharma, discusses the emerging role that LC-MS/MS is playing as an orthogonal tool to help identify and quantify these impurities with exquisite sensitivity.

DOWNLOAD WHITE PAPER

Ligand-binding assays (LBAs) are the most common methods for detection of antidrug antibodies. LBAs offer high throughput as well as excellent sensitivity and specificity; however, they also have their limitations. With advances in instrumentation, approaches using LC-MS have emerged as an adjunct tool to overcome some of the challenges associated with conventional LBAs.

The Alliance team shares perspectives on both platforms and the potential future of immunogenicity testing.

DOWNLOAD WHITE PAPER

ADCs are challenging to develop and analyze for a number of reasons.

Colin Barry, VP of Technology and Bioanalysis at Alliance Pharma, shares his perspective on advantages and disadvantages of using hybrid LBA/LC-MS as a technique to overcome the challenges we face developing these unique classes of compounds.

DOWNLOAD WHITE PAPER